Nurix Revenue and Competitors
Estimated Revenue & Valuation
- Nurix's estimated annual revenue is currently $42.6M per year.
- Nurix's estimated revenue per employee is $144,003
- Nurix's total funding is $330.9M.
Employee Data
- Nurix has 296 Employees.
- Nurix grew their employee count by -1% last year.
Nurix's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CSO | Reveal Email/Phone |
3 | Head Statistical Programming at Nurix Therapeutics | Reveal Email/Phone |
4 | General Counsel and Secretary | Reveal Email/Phone |
5 | SVP Information Technology | Reveal Email/Phone |
6 | SVP, Technical Operations | Reveal Email/Phone |
7 | VP, Market Strategy, New Product Planning and Head the BTK Franchise | Reveal Email/Phone |
8 | VP and Head Program & Portfolio Management | Reveal Email/Phone |
9 | VP, Head Regulatory Affairs | Reveal Email/Phone |
10 | VP Clinical Development | Reveal Email/Phone |
Nurix Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Nurix?
Nurix, Inc. is a leader in discovering and developing therapies that modulate the ubiquitin proteasome system (UPS). The UPS is a regulatory pathway that directs protein degradation, a function vital to the healthy life of a cell, and presents therapeutic opportunities in multiple disease areas, including oncology. Nurix’s state-of–the-art product engine leverages a deep mechanistic understanding of the UPS to deliver effective small molecule drug candidates with the potential to make a dramatic difference for patients. Nurix was founded by internationally recognized experts in the ubiquitin proteasome field and is funded by leading life science investors, Third Rock Ventures and The Column Group. The company is headquartered in San Francisco, California.
keywords:N/A
$330.9M
Total Funding
296
Number of Employees
$42.6M
Revenue (est)
-1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Nurix News
About Nurix Therapeutics, Inc. Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and...
About Nurix Therapeutics, Inc. Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and...
About Nurix Therapeutics, Inc. Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of...
DeTIL-0255 is a drug-enhanced investigational new cell therapy product candidate with potentially superior T cell properties compared to conventional TIL Michael T. Lotze, Nurix’s chief cellular therapy officer, is awarded Lifetime Achievement award by SITC at its annual meeting SAN FRANCISCO, ...
Food and Drug Administration clears DeTIL-0255 to initiate Phase 1 clinical trial Phase 1 clinical trial initiation anticipated by year-end 2021 SAN FRANCISCO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein mod ...
Other Companies in San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $44.5M | 296 | -26% | $153M |
#2 | $70M | 296 | 58% | $66.1M |
#3 | $50.9M | 296 | -6% | $240M |
#4 | $44.7M | 297 | -6% | $165M |
#5 | N/A | 297 | 379% | N/A |